Role of Fetuin-A, as a non-invasive Biomarker in Diagnosis and Assessment of severity of Non-Alcoholic Fatty Liver Disease (NAFLD)

Benha University Hospitals0 个研究点目标入组 100 人开始时间: 2023年9月18日最近更新: 2024年3月4日

适应症

试验速览

暂无简介。

•1.a dull or aching pain in the top right of the tummy (over the lower right side of the ribs)
•2. extreme tiredness
•3.unexplained weight loss
•4.weakness

•1.Patients below the age of 18.
•2.patients with a history of significant alcohol intake exceeding 40 g/d in males and 20 g/d in females over the past 5 years.
•3.presence of concomitant hepatitis B and hepatitis C virus infection.
•4.patients with symptoms and signs suggesting (hemochromatosis, Wilson’s disease, alpha-one anti-trypsin deficiency and autoimmune hepatitis).
•5.patients with hepatobiliary malignancy and pregnant females (unfit for Fibroscan & CAP).
•6.Patients who use these medications; steatogenic drugs (amiodarone, valproic acid, antiretroviral drugs, methotrexate, and tetracyclines), or medicines that are used for the management of NAFLD (Vitamin E, metformin, and thiazolidinediones) .

发起方

Benha University Hospitals